B Cell News and Research

RSS

RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancer

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report."

6 Feb 2025

KAIST team discovers molecular switch to reverse cancer cells

Professor Kwang-Hyun Cho's research team has recently been highlighted for their work on developing an original technology for cancer reversal treatment that does not kill cancer cells but only changes their characteristics to reverse them to a state similar to normal cells.

6 Feb 2025

Testosterone found to worsen heart attack damage

Testosterone worsens the damage caused by a heart attack by increasing the number of white blood cells released from the bone marrow.

6 Feb 2025

New technology unlocks secrets of bacterial gene expression

How do bacteria - harmless ones living in our bodies, or those that cause disease - organize their activities? A new study, combining powerful genomic-scale microscopy with a technical innovation, captured which genes bacteria turn on in different situations and in different spatial environments.

6 Feb 2025

Cannabis use during pregnancy linked to impaired fetal growth

Cannabidiol (CBD), the component in cannabis often used for therapeutic treatments, is increasingly being used during pregnancy as a means of managing symptoms such as nausea, anxiety and sleep.

6 Feb 2025

Gyros Protein Technologies introduces Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to support biotherapeutic development

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers, today announced the introduction of its Gyrolab® HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents.

6 Feb 2025

Advancing living materials with precise control over mechanical properties

Rice University researchers have revealed novel sequence-structure-property relationships for customizing engineered living materials (ELMs), enabling more precise control over their structure and how they respond to deformation forces like stretching or compression.

6 Feb 2025

MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market leader of on-target and off-target editing assessment services for cell and gene therapies.

From MaxCyte, Inc. 6 Feb 2025

Study explores how nanoplastics could affect child's immune system during pregnancy

Allergies and asthma are widespread diseases that could arise during embryonal development in the womb.

6 Feb 2025

How olive oil bioactives regulate genes linked to insulin resistance

Olive oil bioactives, including MUFAs, polyphenols, and triterpenoids, modulate gene expression linked to insulin sensitivity, inflammation, and beta-cell function, offering potential benefits for Type 2 Diabetes Mellitus prevention and management.

5 Feb 2025

Research disproves persister bacteria as main cause of antibiotic resistance

Antibiotics are indispensable for treating bacterial infections. But why are they sometimes ineffective, even when the bacteria are not resistant? In their latest study published in the journal Nature, researchers from the University of Basel challenge the conventional view that a small subset of particularly resilient bacteria are responsible for the failure of antibiotic therapies.

5 Feb 2025

Inhibiting S6K2 gene offers potential treatment for drug-resistant melanoma

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

5 Feb 2025

Breakthrough personalized vaccine shows promising results in kidney cancer trial

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.

5 Feb 2025